HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Hepatocyte growth factor ameliorates progression of interstitial fibrosis in rats with established renal injury.

AbstractBACKGROUND:
Hepatocyte growth factor (HGF) has been reported to prevent injury in several models of renal disease; however, whether HGF can also retard progression of established renal disease is not known.
METHODS:
The aim of the present study was to examine the effects of HGF on progression of chronic renal disease in rats with remnant kidneys and established injury. Studies were performed in rats that underwent subtotal nephrectomy, were observed for two weeks without therapy, and then randomized to receive HGF or vehicle by continuous infusion for an additional two weeks.
RESULTS:
HGF administration was associated with a reduction in morphologic evidence of interstitial, but not glomerular injury. The beneficial effects of HGF were not associated with reductions in the expression of transforming growth factor-beta (TGF-beta), or in the extent epithelial cell apoptosis or transdifferentiation. Rather, HGF appeared to induce fibrinolytic pathways by increasing expression of metalloproteinase-9 (MMP-9) and decreasing levels of plasminogen activator inhibitor-1 (PAI-1) and tissue inhibitor of metalloproteinase-1 (TIMP-2). HGF administration was also associated with an apparent increase in renal endothelin production and a significant reduction in glomerular capillary pressure.
CONCLUSION:
These findings suggest that HGF can retard progression of chronic renal disease even after injury is already established, primarily by promoting matrix degradation.
AuthorsLance D Dworkin, Rujun Gong, Evelyn Tolbert, Jason Centracchio, Nahiro Yano, Abdul R Zanabli, Alfredo Esparza, Abdalla Rifai
JournalKidney international (Kidney Int) Vol. 65 Issue 2 Pg. 409-19 (Feb 2004) ISSN: 0085-2538 [Print] United States
PMID14717911 (Publication Type: Journal Article, Research Support, U.S. Gov't, P.H.S.)
Chemical References
  • Plasminogen Activator Inhibitor 1
  • Vasoconstrictor Agents
  • Angiotensin II
  • Tissue Inhibitor of Metalloproteinase-2
  • Hepatocyte Growth Factor
  • Creatinine
  • Matrix Metalloproteinase 9
Topics
  • Angiotensin II (pharmacology)
  • Animals
  • Apoptosis
  • Cells, Cultured
  • Creatinine (blood)
  • Disease Progression
  • Epithelial Cells (metabolism, pathology)
  • Extracellular Matrix (drug effects, physiology)
  • Fibroblasts (metabolism, pathology)
  • Hepatocyte Growth Factor (pharmacology)
  • Humans
  • Kidney Tubules, Proximal (cytology, drug effects)
  • Male
  • Matrix Metalloproteinase 9 (genetics, metabolism)
  • Nephritis, Interstitial (drug therapy, pathology)
  • Plasminogen Activator Inhibitor 1 (genetics, metabolism)
  • Rats
  • Rats, Sprague-Dawley
  • Tissue Inhibitor of Metalloproteinase-2 (genetics, metabolism)
  • Vasoconstrictor Agents (pharmacology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: